UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549


____________________





FORM 10-Q





(Mark One)





S
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For quarterly period ended March 31, 2009





£
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For the transition period from ___________to___________





Commission file number 000-28790








PHYTOMEDICAL TECHNOLOGIES, INC.


(Exact name of registrant as specified in its charter)





Nevada
87-0429962(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)100 Overlook Drive, 2nd Floor
08540Princeton, New Jersey
(Zip Code)(Address of principal executive offices)





(800) 611-3388


(Registrant’s telephone number, including area code)





Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes T   No o.




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.




Large accelerated filer


Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company)


Smaller reporting company
x






Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act.)  Yes o No T.




Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 200,398,290 shares of Common Stock, par value $0.00001, were outstanding on May 1, 2009.










PHYTOMEDICALTECHNOLOGIES, INC.


FORM 10-Q





For the Quarterly Period Ended March 31, 2009





Table of Contents





PART I    FINANCIAL INFORMATION





Item 1. Consolidated Financial Statements (Unaudited).Consolidated Balance Sheets (Unaudited)

3Consolidated Statements of Operations (Unaudited)

4Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)

5Consolidated Statements of Cash Flows (Unaudited)

6Notes to Consolidated Financial Statements (Unaudited)

7Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations.

12Item 4T.
Controls and Procedures.

18PART II   OTHER INFORMATIONItem 1.
Legal Proceedings.

19Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.

19Item 3.
Defaults Upon Senior Securities.

19Item 4.
Submission of Matters to a Vote of Security Holders.

19Item 5.
Other Information.

19Item 6.
Exhibits.

19SignaturesCertifications




Table of Contents


PART I— FINANCIAL INFORMATION





Item 1. ConsolidatedFinancial Statements (Unaudited)





PHYTOMEDICALTECHNOLOGIES, INC.


CONSOLIDATED BALANCE SHEETS


March 31, 2009 and December 31, 2008


(Expressed in U.S. Dollars)


(Unaudited)





March 31,


December 31,2009


2008ASSETSCurrent assetsCash and cash equivalents

$
534,036


$
665,833Prepaid expenses and other current assets


5,114



2,260Total current assets


539,150



668,093Intangible assets - license fees


15,000



15,000Total assets

$
554,150


$
683,093LIABILITIES AND STOCKHOLDERS' DEFICITCurrent liabilitiesAccounts payable

$
30,455


$
23,397Interest payable


259,192



243,473Notes payable


750,000



750,000Total current liabilities


1,039,647



1,016,870Commitments and ContingenciesStockholders' deficitPreferred stock: $0.25 par value; 1,000,000 authorized, no shares issued and outstanding at March 31, 2009 and December 31, 2008


-



-Common stock: $0.00001 par value; 300,000,000 authorized, 200,398,290 shares issued and outstanding at March 31, 2009 and December 31, 2008


2,004



2,004Additional paid-in capital


26,285,899



26,285,899Accumulated other comprehensive loss


-



(523
)Accumulated deficit


(26,773,400
)


(26,621,157
)Total stockholders' deficit


(485,497
)


(333,777
)Total liabilities and stockholders' deficit

$
554,150


$
683,093








(The accompanying notes are an integral part of these consolidated financial statements)


3
 Table of Contents





PHYTOMEDICALTECHNOLOGIES, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS


For the Three Months Ended March 31, 2009 and 2008


(Expressed in U.S. Dollars)


(Unaudited)





Three Months EndedMarch 31,2009


2008Revenue

$
-


$
-Operating expensesDirectors fees - related party


1,700



3,150Investor relations


-



422,530Wages and benefits


67,905



80,521Research and development


18,323



149,252Professional fees


45,007



22,094Other operating expenses


3,066



61,320Total operating expenses


136,001



738,867Loss from operations


(136,001
)


(738,867
)Other income (expense)Interest income


-



13,401Interest expense


(15,719
)


(26,297
)Loss on dissolution of foreign subsidiary


(523
)


-Foreign exchange loss


-



(1,571
)Total other income (expense)


(16,242
)


(14,467
)Net loss

$
(152,243
)

$
(753,334
)Net loss per common share - basic and diluted

$
(0.00
)

$
(0.00
)Weighted average number of common shares outstanding - basic and diluted


200,398,290



200,398,290








(The accompanying notes are an integral part of these consolidated financial statements)


4
 Table of Contents





PHYTOMEDICALTECHNOLOGIES, INC.


CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)


For the Three Months Ended March 31, 2009 and Year Ended December 31, 2008


(Expressed in U.S. Dollars)


(Unaudited)





Common Stock


Additional


Accumulated Other Comprehensive


Accumulated


Comprehensive


Total Stockholders'Shares


Amount


Paid-in Capital


(Loss) Income


Deficit


Loss


Equity (Deficit)Balance, December 31, 2007


200,398,290


$
2,004


$
26,272,275


$
1


$
(25,060,356
)

$
-


$
1,213,924Stock based compensation expense










13,624















13,624Comprehensive income (loss)Foreign currency translation adjustments














(524
)






(524
)


(524
)Net loss, year ended December 31, 2008


















(1,560,801
)


(1,560,801
)


(1,560,801
)Total comprehensive loss






















(1,561,325
)Balance, December 31, 2008


200,398,290



2,004



26,285,899



(523
)


(26,621,157
)






(333,777
)Comprehensive income (loss)Loss on dissolution of foreign subsidiary














523







523



523Net loss, three months ended March 31, 2009


















(152,243
)


(152,243
)


(152,243
)Total comprehensive loss





















$
(151,720
)Balance, March 31, 2009


200,398,290


$
2,004


$
26,285,899


$
-


$
(26,773,400
)





$
(485,497
)








(The accompanying notes are an integral part of these consolidated financial statements)




5
 Table of Contents





PHYTOMEDICALTECHNOLOGIES, INC.


CONSOLIDATED STATEMENTS OF CASH FLOWS


For the Three Months Ended March 31, 2009 and 2008


(Expressed in U.S. Dollars)


(Unaudited)





Three Months EndedMarch 31,2009


2008Cash flows from operating activitiesNet loss

$
(152,243
)

$
(753,334
)Adjustments to reconcile net loss to net cash used in operating activitiesDepreciation


-



800Stock based compensation


-



13,624Loss on dissolution of foreign subsidiary


523



-Changes in operating assets and liabilities:Increase in prepaid expenses and other current assets


(2,854
)


(3,524
)Increase in accounts payable


7,058



-Increase in accrued liabilities


-



1,563Increase (decrease) in interest payable


15,719



(41,882
)Net cash used in operating activities


(131,797
)


(782,753
)Cash flows from investing activitiesPurchase of equipment


-



(2,300
)Net cash used in investing activities


-



(2,300
)Cash flows from financing activitiesRepayment of loan to stockholder


-



(250,000
)Net cash used in financing activities


-



(250,000
)Effect of foreign exchange rate


-



1Decrease in cash and cash equivalents


(131,797
)


(1,035,052
)Cash and cash equivalents at beginning of period


665,833



2,434,230Cash and cash equivalents at end of period

$
534,036


$
1,399,178Supplemental disclosure of cash flow information:Interest paid in cash

$
-


$
68,179Income tax paid in cash

$
-


$
-








(The accompanying notes are an integral part of these consolidated financial statements)




6
 Table of Contents


PHYTOMEDICALTECHNOLOGIES, INC.


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS





March 31, 2009


(Expressed in U.S. Dollars)


(Unaudited)





Note 1.  Organization and Nature of Operations





PhytoMedical Technologies, Inc. was incorporated in the State of Nevada on July 25, 2001; and together with its wholly owned subsidiaries PhytoMedical Technologies Corporation (“PhytoMedical Corp.”), PolyPhenol Technologies Corporation (“PolyPhenal”) and PhytoMedical Technologies Ltd. (“PhytoMedical Ltd.”)
is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.  PhytoMedical Corp. was incorporated on March 10, 2004 in the State of Nevada and has no assets and liabilities. PolyPhenal was incorporated on August 24, 2004 in the State of Nevada and has no assets and liabilities.  PhytoMedical Ltd. was incorporated on April 11, 2007 in the Province of British Columbia, Canada for providing administrative services to the Company’s Canada office.  The
Company ceased to conduct business in Canada on August 31, 2008 and closed this office. As a result, the Company dissolved PhytoMedical Ltd. and eliminated all intercompany balances, effective January 1, 2009.





PhytoMedical Technologies, Inc., together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.





Note 2.  Going Concern Uncertainties





The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern.  The Company has incurred cumulative losses of $26,773,400 through March 31, 2009, does not have positive cash flows from operating activities, and had negative working capital of $500,497 as of March 31,
2009.  Additionally, the Company has expended a significant amount of cash in developing its technology.  The Company faces all the risks common to companies that are relatively new, including under capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Management recognizes that in
order to meet the Company’s capital requirements, and continue to operate, additional financing will be necessary.  The Company expects to raise additional funds through private or public equity investments in order to expand the range and scope of its business operations. The Company will seek access to private or public equity but there is no assurance that such additional funds will be available for the Company to finance its operations on acceptable terms, if at all. If the Company is unable
to raise additional capital or generate positive cash flow, it is unlikely that the Company will be able to continue as a going concern.





These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying
consolidated financial statements.





Note 3.  Presentation of Interim Information





The accompanying unaudited interim consolidated financial statements have been prepared in accordance with Form 10-Q instructions and in the opinion of management of PhytoMedical Technologies, Inc., include all adjustments (of a normal recurring nature) considered necessary to present fairly the financial position of the Company as of March
31, 2009 and December 31, 2008 and the related results of operations, stockholders’ equity (deficit), and cash flows for the three months ended March 31, 2009 and 2008. These results have been determined on the basis of generally accepted accounting principles and practices in the United States and applied consistently with those used in the preparation of the Company’s 2008 Annual Report on Form 10-K.





Certain information and footnote disclosures normally included in the quarterly financial statements presented in accordance with generally accepted accounting principles in the United States have been condensed or omitted. It is suggested that the accompanying unaudited interim consolidated financial statements be read in conjunction with
the consolidated financial statements and notes thereto incorporated by reference in the Company’s 2008 Annual Report on Form 10-K.





Recently Issued Accounting Standards




In September 2006, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 157, “Fair Value Measurements” (SFAS 157), which establishes a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. In February 2008, the FASB issued FASB Staff Position No. 157-2,
“Effective Date of FASB Statement 157” (FSP 157-2), which allows for the deferral of the adoption date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company was required to adopt SFAS 157 for the assets and liabilities within the scope of FSP 157-2 on January 1, 2009.  The adoption of SFAS 157 for non-financial assets and liabilities and the adoption of
SFAS 157 for those assets and liabilities not subject to the deferral permitted by FSP 157-2 did not have a material impact on the Company’s consolidated financial statements.  In October 2008, the FASB issued SFAS Staff Position No. 157-3, “Determining the Fair Value of a Financial Asset in a Market That Is Not Active” (FSP 157-3), which clarifies the application of SFAS 157 when the market for a financial asset is inactive. The guidance in FSP 157-3 was effective immediately
and did not have a material effect on the Company’s consolidated financial statements.


7
 Table of Contents




In June 2008, the FASB issued Staff Position EITF 03-06-1, “Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities” (FSP EITF 03-06-1). FSP EITF 03-06-1 provides that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents
(whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method in SFAS No. 128, “Earnings per Share.”   FSP EITF 03-06-1 must be adopted for reporting periods beginning after December 15, 2008.  FSP EITF 03-06-1 did not have any impact on the Company’s consolidated financial statements.





In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an Amendment of Accounting Research Bulletin No 51” (SFAS 160). SFAS 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, changes in
a parent’s ownership of a noncontrolling interest, calculation and disclosure of the consolidated net income attributable to the parent and the noncontrolling interest, changes in a parent’s ownership interest while the parent retains its controlling financial interest and fair value measurement of any retained noncontrolling equity investment. SFAS 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years.
Early adoption is prohibited. SFAS 160 did not have a material effect on the Company’s consolidated financial statements.





In December 2007, the FASB issued SFAS No. 141R, “Business Combinations” (SFAS 141R), which establishes principles and requirements for the reporting entity in a business combination, including recognition and measurement in the financial statements of the identifiable assets acquired, the liabilities assumed, and any noncontrolling
interest in the acquiree. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period on or after December 15, 2008, and interim periods within those fiscal years. SFAS 141R did not have a material effect on the Company’s consolidated financial statements.





Note 4.  Net Loss per Share





Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of common and dilutive common equivalent shares outstanding during the period.  As
the Company had a net loss in each of the periods presented, basic and diluted net loss per share are the same.





Excluded from the computation of diluted net loss per share for the three months ended March 31, 2009 and 2008, because their effect would be antidilutive, are stock options and warrants to acquire 12,897,081 shares of common stock with a weighted-average exercise price of $0.42 per share.





For purposes of earnings per share computations, shares of common stock that are issuable at the end of a reporting period are included as outstanding.





Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2009 and 2008:





Three Months EndedMarch 31,2009


2008Numerator - net loss

$
(152,243
)

$
(753,334
)Denominator - weighted average number of common shares outstanding - basic and diluted


200,398,290



200,398,290Basic and diluted net loss per common share

$
(0.00
)

$
(0.00
)


8
 Table of Contents


Note 5.  Iowa State University Sponsored Research Agreement





Iowa State University Sponsored Research Agreement





On February 1, 2007, the Company, through its wholly owned subsidiary, PolyPhenol Technologies Corporation, entered into a Sponsored Research Agreement with Iowa State University (“ISU”). Under terms of the agreement, the Company continued to undertake its research at ISU for development of the Company’s novel, synthesized
type A-1 ‘polyphenolic’ compounds.  On January 6, 2009, the Company provided written notice to ISU terminating the Sponsored Research Agreement between the Company and ISU. The termination was effective March 6, 2009.





Contractual Obligations under the ISU Sponsored Research Agreement were as follows:





Year 1: $62,251 (paid as of March 31, 2009) to ISU in 4 quarterly installments, the first of which was due within 30 days of signing of the Sponsored Research Agreement, the second of which was due to ISU 3 months from the previous payment;





Year 2: $70,295 ($52,721 of which was paid as of March 31, 2009) to ISU in 4 quarterly installments, the first of which was due to ISU 3 months from the previous payment; and





Year 3: $72,140 to ISU in 4 quarterly installments, the first of which was due to ISU 3 months from the previous payment.





Upon written notice of termination of the Sponsored Research Agreement to ISU on January 6, 2009, the Company was current with respect to all contractual obligations owed to ISU pursuant to the Sponsored Research Agreement.





As of March 31, 2009, the Company had paid a total of $114,972 pursuant to the terms of the ISU Sponsored Research Agreement of which $0 and $15,563 is included in research and development expense for the three months ended March 31, 2009 and 2008.  In addition to contractual obligations pursuant to the ISU Sponsored Research
Agreement, the Company reimbursed ISU $0 and $414 during the three months ended March 31, 2009 and 2008 for other out-of-pocket costs that are included in research and development expense.





Note 6.  Iowa State University Research Foundation License Agreement





On June 12, 2006, the Company, through its wholly owned subsidiary, PolyPhenol Technologies Corporation, entered into an exclusive license agreement with Iowa State University Research Foundation Inc. (“ISURF”) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols, which have been linked
to insulin sensitivity by the USDA's Agricultural Research Service.  On January 6, 2009, the Company gave written notice to ISURF terminating the License Agreement between the Company and ISURF. The termination is effective April 6, 2009.





Under terms of the license agreement, the Company had to pay ISURF license fees, of which $20,000 was payable (paid) within 30 days of execution of the agreement, $50,000 was payable upon completion of the first successful Phase 2 clinical trial and the remaining $250,000 was payable upon first approval by the regulatory authority on new
drug application. The Company also had to reimburse ISURF the cost incurred for filing, prosecuting and maintaining the licensed patents together with 15% of the said costs, not exceeding $10,000, as the administration fee.





Upon written notice of termination of the license agreement to ISURF on January 6, 2009, the Company was current with respect to all contractual obligations owed to ISURF pursuant to the license agreement.





As of March 31, 2009, the Company had paid a total of $20,000 to ISURF for the license fee and $31,223 for reimbursement of patent costs and research expenses as per agreement with ISURF, none of which is included in research and development expense for the three months ended March 31, 2009 and 2008.





Note 7.  Ricerca Development Agreements





The Company utilizes Ricerca BioSciences LLC (“Ricerca”) as a research vendor, on an as needed basis, to assist in the development of the Company’s technologies.  The terms and scope of the work that Ricerca performs is in accordance with formalized statements of work.





During the three months ended March 31, 2009 and 2008, the Company incurred $5,400 and $41,100 for services provided by Ricerca, which is included in research and development expense.


9
 Table of Contents


Note 8.  Dartmouth Sponsored Research Agreement





On May 25, 2007, the Company entered into a Sponsored Research Agreement with Dartmouth College (“Dartmouth”), in the area of cancer research, specifically furthering research and development of anti-tumor bis-acridines. The Sponsored Research Agreement with Dartmouth was amended on October 1, 2008 extending it to September
30, 2009.  Dartmouth granted the Company the option of a world-wide, royalty-bearing exclusive license to make, have made, use and sell in the field of oncology, the products embodying or produced through Dartmouth’s previous and future patents and through any joint-inventions related to the agreement, at reasonable terms and conditions as the parties may agree.





The Company will reimburse Dartmouth for all costs associated with obtaining and maintaining Dartmouth’s pre-existing patents related to the subject technology.





As of March 31, 2009, the Company has paid a total of $172,800 pursuant to the Sponsored Research Agreement with Dartmouth, of which $11,750 and $92,715 is included in research and development expense for the three months ended March 31, 2009 and 2008.





Note 9.  Dartmouth License Agreement





On September 1, 2008, the Company entered into an exclusive license agreement with the Trustees of Dartmouth College (“DC”) to develop, market and distribute a novel class of synthesized compounds known as bis-intercalators.  These anti-cancer agents which have a ‘cytotoxic’ or poisonous affinity for cancer
cells, and are designed to bind tightly to cancer cell DNA (deoxyribonucleic acid), the blueprint of life for the cancer cell.





Under the terms of the license agreement, the Company has to pay license fees to DC based upon milestones, in addition to an upfront payment of $15,000 (paid) within 30 days of execution of the agreement.   In addition, DC will receive royalty payments on the net sales of products.   The Company will pay an
annual royalty throughout the duration of the agreement.   The Company also has to reimburse DC the costs incurred for filing, prosecuting and maintaining the licensed patents. The Company will administer the development, regulatory approval, and commercialization of the compounds and pursue future collaborative arrangements.





The Company submitted a Confidential Treatment (“CT”) Request with the United States Securities and Exchange Commission (the “SEC”) on October 22, 2008.  On March 9, 2009, the SEC granted the confidential treatment of the Dartmouth License Agreement to the Company. Accordingly, the terms of the license agreement
do not need to be released to the public until August 5, 2013.





Note 10.  Stock Options





On July 12, 2001, the Company approved its 2001 Stock Option Plan (the “2001 Plan”), which has 10,000,000 shares reserved for issuance thereunder, all of which were registered under Form S-8 on October 2, 2003. On July 25, 2005, the Company approved its 2005 Stock Option Plan (the “2005 Plan”), which has 15,000,000
shares reserved for issuance thereunder. The 2001 Plan and 2005 Plan provides shares available for options granted to employees, directors and others. The options granted to employees under the Company’s option plans generally vest over two to five years or as otherwise determined by the plan administrator. Options to purchase shares expire no later than ten years after the date of grant.





A summary of the Company’s stock option activity for the three months ended March 31, 2009 and related information follows:





Number of Options


Weighted Average Exercise Price

Weighted Average Remaining Contractual Term

Aggregate Intrinsic ValueOutstanding at December 31, 2008 and March 31, 2009


2,000,000


$
0.52

7.34 years

$
-Exercisable at March 31, 2009


-Available for grant at March 31, 2009


20,250,000





The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of shares) that would have been received by the
option holders had all option holders exercised their options on March 31, 2009. The intrinsic value changes based on the fair market value of the Company’s common stock.


10
 Table of Contents


At March 31, 2009 and December 31, 2008 the Company had unvested stock options to purchase 2,000,000 shares of the Company’s common stock at a grant date fair value per share of $0.48.





During the three months ended March 31, 2009 and 2008, stock-based compensation expense of $0 and $13,624 was recognized for options previously granted, which is included in wages and benefits.  As of March 31, 2009, the Company had no unrecognized compensation cost related to unvested stock options.





The following table summarizes information about stock options outstanding and exercisable at March 31, 2009:





Stock Options Outstanding


Stock Options ExercisableNumber of Options


Weighted Average Remaining Contractual


Weighted Average Exercise


Number of Options


Weighted Average Remaining Contractual


Weighted Average ExerciseExercise Price


Outstanding


Life (Years)


Price


Exercisable


Life (Years)


Price$
0.52



2,000,000



7.34


$
0.52



—



—


$
—





The Company does not repurchase shares to fulfill the requirements of stock options that are exercised. Further, the Company issues new shares when stock options are exercised.





Note 11.  Warrants





As of March 31, 2009, there were 10,897,081 warrants outstanding. Each warrant entitles the holder to purchase one share of the common stock of the Company at an exercise price of $0.40 per share until September 25, 2010.





Note 12.  Related Party Transactions





Wages and benefits





During the three months ended March 31, 2009 and 2008, the Company incurred $67,905 and $66,897 in cash wages and benefits expense for services rendered by Mr. Greg Wujek, the President, Chief Executive Officer, and Director of the Company.





During the three months ended March 31, 2008, the Company also recorded $13,624 in stock based compensation expense related to the amortization of a stock option previously granted to Mr. Wujek to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.52 per share, which is included in wages and benefits.





Director fees





During the three months ended March 31, 2009 and 2008, the Company incurred $1,700 and $3,150 in non-employee director fees.





Notes payable





The Company had arranged with Mr. Harmel S. Rayat, former Chief Financial Officer, Director, and majority shareholder of the Company, a loan amount up to $2,500,000 that may be drawn down on an “as needed basis” at a rate of prime plus 3%.  Effective September 15, 2008, Mr. Rayat and the Company terminated this loan
agreement.  During the three months ended March 31, 2008, the Company repaid $250,000 to Mr. Rayat with the accrued interest of $67,664.  At March 31, 2009, the Company had an unsecured promissory note pursuant to this loan agreement in the amount of $750,000 payable to Mr. Rayat, which was due on March 8, 2006 and bears interest at an annual rate of 8.50%.  At March 31, 2009, accrued interest on the $750,000 remaining promissory note was $259,192 and is included in interest payable.  The
entire principal and accrued interest is due and payable on demand.





All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.


11
 Table of Contents


Item2.  Management’s discussion and Analysis of Financial Condition and Results of Operations.




Forward-Looking Statements





Except for the historical information presented in this document, the matters discussed in this Form 10-Q for the three months ended March 31, 2009, and specifically in the items entitled "Management’s Discussion and Analysis of Financial Condition and Results of Operations," or otherwise incorporated by reference into this document,
contain "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are identified by the use of forward-looking terminology such as "believes," "plans," "intend," "scheduled," "potential," "continue," "estimates," "hopes," "goal," "objective," expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties.





The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by the Company. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future
performance or results. These forward-looking statements involve risks and uncertainties, including those identified within this Form 10-Q. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in this
Form 10-Q and in the Company's other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that may affect the Company's business.





Overview





PhytoMedical Technologies, Inc. was incorporated in the State of Nevada on July 25, 2001; and together with its wholly owned subsidiaries PhytoMedical Technologies Corporation (“PhytoMedical Corp.”), PolyPhenol Technologies Corporation (“PolyPhenal”) and PhytoMedical Technologies Ltd. (“PhytoMedical Ltd.”)
is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.  PhytoMedical Corp. was incorporated on March 10, 2004 in the State of Nevada and has no assets and liabilities. PolyPhenal was incorporated on August 24, 2004 in the State of Nevada and has no assets and liabilities.  PhytoMedical Ltd. was incorporated on April 11, 2007 in the Province of British Columbia, Canada for providing administrative services to the Company’s Canada office.  As
a result, the Company dissolved PhytoMedical Ltd. and eliminated all intercompany balances, effective January 1, 2009.





PhytoMedical Technologies, Inc., together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.





Because the Company is a smaller reporting company, certain disclosures otherwise required to be made in a Form 10-Q are not required to be made by the Company.





Cancer Research





Dartmouth Sponsored Research Agreement





Pursuant to the Company’s Sponsored Research Agreement with Dartmouth College (“Dartmouth”), which was amended on October 1, 2008 extending it to September 30, 2009, it is synthesizing and testing a novel class of anti-cancer agents which have a ‘cytotoxic’ or poisonous affinity for cancer cells, and are designed
to bind tightly to cancer cell DNA (deoxyribonucleic acid), the blueprint of life for the cancer cell. Previous studies conducted by Dartmouth using a leukemia mouse cell line, have demonstrated that such binding (or intercalation) should stop the replication of the DNA, and, ultimately, lead to the death of the cancer cell.  Following the preparation of starting materials, researchers will design, synthesize and test new examples of compounds known to bind to DNA, called bis-acridines; these bis-acridines
will be tethered to the DNA with both flexible and semi-rigid linking chains.  If successfully synthesized, the compounds will be submitted for evaluation in human cancer cell lines.





Depending on research outcomes, the Company plans to fund various in vitro (test tube) and in vivo (animal) experiments that will involve the use of several commercially available human cancer cell lines covering key areas of concern such as glioblastoma (tumors related to the central nervous system, including but not limited to the brain,
spinal cord and optic nerve), small cell lung, breast, kidney, pancreatic, and liver cancers.  The Company’s goal, based on the results of both the in vitro and in vivo tests, will involve identification of the key compound(s) that demonstrated the greatest anti-cancer activity per human cancer cell line.





On February 3, 2009, PhytoMedical Technologies, Inc. issued a news release to announce results from recent in vivo efficacy and toxicity tests where the Company’s patented anti-cancer compound was administered to specimens with difficult-to-treat human brain cancer (SF295 glioblastoma xenografts) and, according to researchers, proved
to be least toxic and effective in controlling the growth of SF295 human glioblastoma xenografts.


12
 Table of Contents


Based on the results, the Company is currently creating an Intra Venous (IV) formulation to be tested in vivo for efficacy and toxicity.  Additionally the Company plans on conducting a pharmacologic study on the IV formulation.





Dartmouth granted the Company the option of a world-wide, royalty-bearing exclusive license to make, have made, use and sell in the field of oncology, the products embodying or produced through Dartmouth’s previous and future patents and through any joint-inventions related to the agreement, at reasonable terms and conditions as the
parties may agree.





The Company will reimburse Dartmouth for all costs associated with obtaining and maintaining Dartmouth’s pre-existing patents related to the subject technology.





As of March 31, 2009, the Company has paid a total of $172,800 pursuant to the Sponsored Research Agreement with Dartmouth, of which $11,750 and $92,715 is included in research and development expense for the three months ended March 31, 2009 and 2008.





Dartmouth License Agreement





On September 1, 2008, the Company entered into an exclusive license agreement with the Trustees of Dartmouth College (“DC”) to develop, market and distribute a novel class of synthesized compounds known as bis-intercalators.  These anti-cancer agents which have a ‘cytotoxic’ or poisonous affinity for cancer
cells, and are designed to bind tightly to cancer cell DNA (deoxyribonucleic acid), the blueprint of life for the cancer cell.





Under the terms of the license agreement, the Company has to pay license fees to DC based upon milestones, in addition to an upfront payment of $15,000 (paid) within 30 days of execution of the agreement.   In addition, DC will receive royalty payments on the net sales of products.   The Company will pay an
annual royalty throughout the duration of the agreement.   The Company also has to reimburse DC the costs incurred for filing, prosecuting and maintaining the licensed patents. The Company will administer the development, regulatory approval, and commercialization of the compounds and pursue future collaborative arrangements.





The Company submitted a Confidential Treatment (“CT”) Request with the United States Securities and Exchange Commission (the “SEC”) on October 22, 2008.  On March 9, 2009, the SEC granted the confidential treatment of the Dartmouth License Agreement to the Company. Accordingly, the terms of the license agreement
do not need to be released to the public until August 5, 2013.





Diabetes Research





Iowa State University Sponsored Research Agreement





On February 1, 2007, the Company, through its wholly owned subsidiary, PolyPhenol Technologies Corporation, entered into a Sponsored Research Agreement with Iowa State University (“ISU”). Under terms of the agreement, the Company continued to undertake its research at ISU for development of the Company’s novel, synthesized
type A-1 ‘polyphenolic’ compounds.  On January 6, 2009, the Company provided written notice to ISU terminating the Sponsored Research Agreement between the Company and ISU. The termination was effective March 6, 2009.





Contractual Obligations under the ISU Sponsored Research Agreement were as follows:





Year 1: $62,251 (paid as of March 31, 2009) to ISU in 4 quarterly installments, the first of which was due within 30 days of signing of the Sponsored Research Agreement, the second of which was due to ISU 3 months from the previous payment;





Year 2: $70,295 ($52,721 of which was paid as of March 31, 2009) to ISU in 4 quarterly installments, the first of which was due to ISU 3 months from the previous payment; and





Year 3: $72,140 to ISU in 4 quarterly installments, the first of which was due to ISU 3 months from the previous payment.





Upon written notice of termination of the Sponsored Research Agreement to ISU on January 6, 2009, the Company was current with respect to all contractual obligations owed to ISU pursuant to the Sponsored Research Agreement.





As of March 31, 2009, the Company had paid a total of $114,972 pursuant to the terms of the ISU Sponsored Research Agreement of which $0 and $15,563 is included in research and development expense for the three months ended March 31, 2009 and 2008.  In addition to contractual obligations pursuant to the ISU Sponsored Research
Agreement, the Company reimbursed ISU $0 and $414 during the three months ended March 31, 2009 and 2008 for other out-of-pocket costs that are included in research and development expense.


13
 Table of Contents


Iowa State University Research Foundation License Agreement





On June 12, 2006, the Company, through its wholly owned subsidiary, PolyPhenol Technologies Corporation, entered into an exclusive license agreement with Iowa State University Research Foundation Inc. (“ISURF”) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols, which have been linked
to insulin sensitivity by the USDA's Agricultural Research Service.  On January 6, 2009, the Company gave written notice to ISURF terminating the License Agreement between the Company and ISURF. The termination is effective April 6, 2009.





Under terms of the license agreement, the Company had to pay to ISURF license fees, of which $20,000 was payable (paid) within 30 days of execution of the agreement, $50,000 was payable upon completion of the first successful Phase 2 clinical trial and the remaining $250,000 was payable upon first approval by the regulatory authority on
new drug application. The Company also had to reimburse ISURF the cost incurred for filing, prosecuting and maintaining the licensed patents together with 15% of the said costs, not exceeding $10,000, as the administration fee.





Upon written notice of termination of the license agreement to ISURF on January 6, 2009, the Company was current with respect to all contractual obligations owed to ISURF pursuant to the license agreement.





As of March 31, 2009, the Company had paid a total of $20,000 to ISURF for the license fee and $31,223 for reimbursement of patent costs and research expenses as per agreement with ISURF, none of which is included in research and development expense for the three months ended March 31, 2009 and 2008.





Ricerca Development Agreements





The Company utilizes Ricerca BioSciences LLC (“Ricerca”) as a research vendor, on an as needed basis, to assist in the development of the Company’s technologies.  The terms and scope of the work that Ricerca performs is in accordance with formalized statements of work.





During the three months ended March 31, 2009 and 2008, the Company incurred $5,400 and $41,100 for services provided by Ricerca, which is included in research and development expense.





Results of Operations





A summary of the Company’s operating expense for the three months ended March 31, 2009 and 2008 was as follows:





Three Months Ended March 31,


Percentage2009


2008


ChangeOperating expensesDirector fees - related party

$
1,700


$
3,150



(46
) %Investor relations


-



422,530



(100
)Wages and benefits


67,905



80,521



(16
)Research and development


18,323



149,252



(88
)Professional fees


45,007



22,094



104Other operating expenses


3,066



61,320



(95
)Total operating expenses

$
136,001


$
738,867



(82
) %




Director fees – related party





Non-employee directors receive $250 per month for their services as directors plus $100 for each board meeting attended.





The decrease in director fees is partially the result of a former director who resigned in September 2007 receiving $850 in January 2008 for services rendered as a non-employee director during fiscal year 2007.  In addition, the three months ended March 31, 2008 includes $750 for director fees that were earned during the quarter
ended December 31, 2007. The amount was not deemed significant to the consolidated financial statements taken as a whole.


14
 Table of Contents




Investor relations





Investor relations costs represent fees paid to publicize the Company’s technology within the investor community with the purpose of increasing company recognition and branding, and to facilitate the efforts to raise funds in equity or debt financings.





During the three months ended March 31, 2008, the Company ramped up its production of newsletters, analyst coverage, and information distribution to the investor community as a result of technological advances made pursuant to the Sponsored Research Agreement with Dartmouth at the end of the fiscal year 2007 and the beginning of the fiscal
year 2008, resulting in significant investor relations expense during the three months ended March 31, 2008 compared to the three months ended March 31, 2009.





Wages and benefits





During the three months ended March 31, 2009 and 2008, the Company incurred $67,905 and $66,897 in cash wages and benefits expense for services rendered by Mr. Greg Wujek, the President, Chief Executive Officer, and Director of the Company.





During the three months ended March 31, 2008, the Company also recorded $13,624 in stock based compensation expense related to the amortization of a stock option previously granted to Mr. Wujek to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.52 per share, which is included in wages and benefits.




Research and development





Research and development costs represent costs incurred to develop the Company’s technologies and are incurred pursuant to the Company’s sponsored research agreements with Dartmouth, ISU, Ricerca, and other third party contract research organizations. The sponsored research agreements include salaries and benefits for research
and development personnel, allocated overhead and facility occupancy costs, contract services and other costs. The Company charges all research and development expenses to operations as they are incurred, except for prepayments which are capitalized and amortized over the applicable period.





Following is a summary of research and development expense incurred for the three months ended March 31, 2009 and 2008:





Three Months EndedMarch 31,


Increase/2009


2008


(Decrease)Research and development expenseISU Sponsored Research Agreement

$
-


$
15,563


$
(15,563
)Dartmouth Sponsored Research Agreement


11,750



92,175



(80,425
)Ricerca


5,400



41,100



(35,700
)Other research and development expense, including out-of-pocket costs


1,173



414



759Total research and development expense

$
18,323


$
149,252


$
(130,929
)





Professional fees





Professional fees substantially consist of accounting fees, audit and tax fees, legal fees, and SEC related filing costs.





Professional fees increased $22,913 during the three months ended March 31, 2009 compared to the same period in 2008 substantially due to an increase in accounting, audit and tax fees of approximately $15,200 and an increase in legal fees of approximately $8,400.  This increase is partially the result of the Company closing its
administrative office in Vancouver, British Columbia, Canada, effective August 31, 2008, terminating all of the employees in Vancouver, Canada.  Due to this downsizing, as of September 1, 2008, the Company began outsourcing its accounting function to third parties resulting in an increase in accounting fees.





Other operating expenses





Other operating expenses include travel and entertainment, rent, office supplies, printing and mailing, information technology related fees and other administrative costs.





Other operating expenses decreased $58,254 during the three months ended March 31, 2009 compared to the same period in 2008 substantially due to decreases in travel and entertainment of $26,456, office supplies, printing and mailing of $12,842, rent of $5,317, and office repair and maintenance of $6,670, as a result of the Company closing
its administrative office in Vancouver, Canada, effective August 31, 2008.


15
 Table of Contents




Other income (expense)





A summary of the Company’s other income (expense) for the three months ended March 31, 2009 and 2008 was as follows:





Three Months EndedMarch 31,


Percentage2009


2008


ChangeOther income (expense)Interest income

$
-


$
13,401



(100
) %Interest expense


(15,719
)


(26,297
)


(40
)Loss on dissolution of foreign subsidiary


(523
)


-



*Foreign exchange loss


-



(1,571
)


(100
)Total other income (expense)

$
(16,242
)

$
(14,467
)


12
%





* Not meaningful





Interest income





As a result of the Company closing its administrative office in Vancouver, Canada, effective August 31, 2008 and the dissolution of PhytoMedical Technologies Ltd., the Company closed its interest bearing bank account on December 31, 2008.





Interest expense





Interest expense decreased $10,578 during the three months ended March 31, 2009 compared to the same period in 2008 as a result of the Company repaying the principal balance of $250,000 of a note payable in February 2008.





Loss on dissolution of foreign subsidiary





PhytoMedical Technologies Ltd. (“PhytoMedical Ltd.”) provided administrative services to the Company’s Canadian office. The Company ceased to conduct business in Canada, effective August 31, 2008 and closed this office. As a result, the Company dissolved PhytoMedical Ltd. and eliminated all intercompany balances.  In
accordance with SFAS No. 52, “Foreign Currency Translation”, the Company recorded a loss on its investment in PhytoMedical Ltd. equal to the accumulated other comprehensive income at December 31, 2008, the time of the dissolution.





Liquidity and Capital Resources





The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern.  The Company has incurred cumulative losses of $26,773,400 through March 31, 2009, does not have positive cash flows from operating activities, and had negative working capital of $500,497 as of March 31,
2009.  Additionally, the Company has expended a significant amount of cash in developing its technology.  The Company faces all the risks common to companies that are relatively new, including under capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Management recognizes that in
order to meet the Company’s capital requirements, and continue to operate, additional financing will be necessary.  The Company expects to raise additional funds through private or public equity investments in order to expand the range and scope of its business operations. The Company will seek access to private or public equity but there is no assurance that such additional funds will be available for the Company to finance its operations on acceptable terms, if at all. If the Company is unable
to raise additional capital or generate positive cash flow, it is unlikely that the Company will be able to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.





The Company's principal source of liquidity is cash in the bank.  At March 31, 2009, the Company had cash and cash equivalents of $534,036. The Company has financed its operations primarily from funds received pursuant to a private placement completed by the Company in September 2007, raising net proceeds of $3,109,500.





Net cash used in operating activities was $131,797 for the three months ended March 31, 2009 compared to $782,753 for the same period in 2008.  The decrease of $650,956 in cash used was substantially due to decreases in investor relations expense of $422,530, research and development expense of $130,929, and other operating expenses
of $58,254 during the three months ended March 31, 2009 compared to 2008.  See “Results of Operations” above for further discussion regarding the decrease in these expenses.





Net cash used in investing activities was $0 for the three months ended March 31, 2009 compared to $2,300 during the same period in 2008.  During the three months ended March 31, 2008, the Company purchased $2,300 of equipment.


16
 Table of Contents


Net cash used in financing activities was $0 for the three months ended March 31, 2009 compared to $250,000 for the same period in 2008.  During the three months ended March 31, 2008, the Company repaid $250,000 of the outstanding principal balance on its notes payable.





Related Party Transactions





Wages and benefits





During the three months ended March 31, 2009 and 2008, the Company incurred $67,905 and $66,897 in cash wages and benefits expense for services rendered by Mr. Greg Wujek, the President, Chief Executive Officer, and Director of the Company.





During the three months ended March 31, 2008, the Company also recorded $13,624 in stock based compensation expense related to the amortization of a stock option previously granted to Mr. Wujek to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.52 per share, which is included in wages and benefits.





Director fees





During the three months ended March 31, 2009 and 2008, the Company incurred $1,700 and $3,150 in non-employee director fees.





Notes payable





The Company had arranged with Mr. Harmel S. Rayat, former Chief Financial Officer, Director, and majority shareholder of the Company, a loan amount up to $2,500,000 that may be drawn down on an “as needed basis” at a rate of prime plus 3%.  Effective September 15, 2008, Mr. Rayat and the Company terminated this loan
agreement.  During the three months ended March 31, 2008, the Company repaid $250,000 to Mr. Rayat with the accrued interest of $67,664.  At March 31, 2009, the Company had an unsecured promissory note pursuant to this loan agreement in the amount of $750,000 payable to Mr. Rayat, which was due on March 8, 2006 and bears interest at an annual rate of 8.50%.  At March 31, 2009, accrued interest on the $750,000 remaining promissory note was $259,192 and is included in interest payable.  The
entire principal and accrued interest is due and payable on demand.





All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.





Other Contractual Obligations





The Company does not have any contractual obligations other than the Sponsored Research and License Agreements, Notes Payable and Accrued Interest, as discussed above.





Off-Balance Sheet Arrangements





The Company has no off-balance sheet arrangements.





Recently Issued Accounting Pronouncements





See Note 3.  “Presentation of Interim Information” to the Consolidated Financial Statements in this Form 10-Q.


17
 Table of Contents


Item4T.   Controls and Procedures





(a) Evaluation of Disclosure Controls and Procedures





Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded as of March 31, 2009 that the Company’s disclosure controls and procedures were effective such that the information required to be disclosed in the Company’s United States Securities and Exchange Commission (the “SEC”) reports is recorded, processed,
summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.





(b) Changes in Internal Control over Financial Reporting





There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting.


18
 Table of Contents


PART II – OTHER INFORMATION





Item1.   Legal Proceedings.





None





Item2.   Unregistered Sales of Equity Securities and Use of Proceeds.





None





Item3.   Defaults Upon Senior Securities.





None





Item4.   Submission of Matters to a Vote of Security Holders.





None





Item5.   Other Information.





None





Item6.   Exhibits.





31.1
Certification of Principal Executive Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *





31.2
Certification of Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *





32.1
Certification of Principal Executive Officer Pursuant to 18 USC. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *





32.2
Certification of Principal Financial Officer Pursuant to 18 USC. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *





____________________





*Filed herewith.


19
 Table of Contents


SIGNATURES





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned  thereunto duly  authorized.





PhytoMedical Technologies, Inc.(Registrant)May 14, 2009
By: /s/ Greg WujekGreg WujekPresident, Chief Executive Officer, DirectorMay 14, 2009
/s/ Raymond KraussChief Financial Officer, Secretary, Treasurer, Director






20